Manufacturer of Controlled Substances; Notice of Application; Alltech Associates, Inc., 70188 [2012-28493]
Download as PDF
<![CDATA[
70188
Federal Register / Vol. 77, No. 226 / Friday, November 23, 2012 / Notices
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 22, 2013.
company is granted registration as an
importer of the basic classes of
controlled substances listed.
Dated: November 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: November 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–28485 Filed 11–21–12; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2012–28486 Filed 11–21–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Application;
Cayman Chemical Company
Drug Enforcement Administration
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 25,
2012, Cayman Chemical Company, 1180
East Ellsworth Road, Ann Arbor,
Michigan 48108, made application to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
JWH–250 (6250) ..........................
SR–18 also known as RCS–8
(7008).
JWH–019 (7019) ..........................
JWH–081 (7081) ..........................
SR–19 also known as RCS–4
(7104).
JWH–122 (7122) ..........................
AM–2201 (7201) ...........................
JWH–203 (7203) ..........................
2C–T–2 (7385) .............................
JWH–398 (7398) ..........................
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
2C–D (7508) .................................
2C–E (7509) .................................
2C–H (7517) .................................
2C–I (7518) ..................................
2C–C (7519) .................................
2C–N (7521) .................................
2C–P (7524) .................................
2C–T–4 (7532) .............................
AM–694 (7694) .............................
Phenylacetone (8501) ..................
17:03 Nov 21, 2012
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 14,
2012, Alltech Associates Inc., 2051
Waukegan Road, Deerfield, Illinois
60015, made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Jkt 229001
By Notice dated July 17, 2012, and
published in the Federal Register on
July 26, 2012, 77 FR 43863, Boehringer
Ingelheim Chemicals, Inc., 2820 N.
Normandy Drive, Petersburg, Virginia
23805–9372, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Tapentadol (9780) ........................
Schedule
II
II
II
II
II
II
Dated: November 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: November 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–28493 Filed 11–21–12; 8:45 am]
[FR Doc. 2012–28496 Filed 11–21–12; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
Schedule
2C-T-2
(2-(4-Ethylthio-2,5dimethoxyphenyl)ethanamine)
(7385).
2C-1
(2-(4-lodo-2,5dimethoxyphenyl) Ethanamine)
(7518).
2C-C
(2-(4-Chloro-2,5dimethoxyphenyl) ethanamine
(7519).
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Manufacturer of Controlled
Substances; Notice of Registration;
Boehringer Ingelheim Chemicals, Inc.
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 22, 2013.
Drug
I
I
I
Drug Enforcement Administration
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals. In
reference to Methadone Intermediate
(9254) the company plans to produce
Methadone HCL active pharmaceutical
ingredients (APIs) for sale to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Boehringer Ingelheim Chemicals, Inc.,
to manufacture the listed basic classes
of controlled substances is consistent
with the public interest at this time.
DEA has investigated Boehringer
Ingelheim Chemicals, Inc., to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
I
I
The company plans to manufacture
the listed controlled substances for
distribution to their research and
forensics customers conducting drug
testing and analysis.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
VerDate Mar<15>2010
Manufacturer of Controlled
Substances; Notice of Application;
Alltech Associates, Inc.
DEPARTMENT OF JUSTICE
PO 00000
Frm 00053
Fmt 4703
Sfmt 9990
I
I
I
E:\FR\FM\23NON1.SGM
23NON1
]]>Agencies
[Federal Register Volume 77, Number 226 (Friday, November 23, 2012)]
[Notices]
[Page 70188]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-28493]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Alltech Associates, Inc.
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on September 14, 2012, Alltech
Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made
application to the Drug Enforcement Administration (DEA) to be
registered as a bulk manufacturer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
2C-T-2 (2-(4-Ethylthio-2,5- I
dimethoxyphenyl)ethanamine) (7385).
2C-1 (2-(4-lodo-2,5-dimethoxyphenyl) I
Ethanamine) (7518).
2C-C (2-(4-Chloro-2,5-dimethoxyphenyl) I
ethanamine (7519).
------------------------------------------------------------------------
The company plans to manufacture high purity drug standards used
for analytical applications only in clinical, toxicological, and
forensic laboratories.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than January 22, 2013.
Dated: November 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-28493 Filed 11-21-12; 8:45 am]
BILLING CODE 4410-09-P
